Designing a broad-spectrum integrative approach for cancer prevention and treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43910964" target="_blank" >RIV/00216208:11120/15:43910964 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.semcancer.2015.09.007" target="_blank" >http://dx.doi.org/10.1016/j.semcancer.2015.09.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.semcancer.2015.09.007" target="_blank" >10.1016/j.semcancer.2015.09.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Popis výsledku v původním jazyce

Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominate

Název v anglickém jazyce

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Popis výsledku anglicky

Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominate

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Seminars in Cancer Biology

ISSN

1044-579X

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

Suppl.

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

29

Strana od-do

"S276"-"S304"

Kód UT WoS článku

000366619400013

EID výsledku v databázi Scopus

—